# Can SS-31 (Elamipretide) reduce oxidative stress in atherosclerosis?

Canonical source: https://retacompare.com/research/can-ss-31-elamipretide-reduce-oxidative-stress-in-atherosclerosis

Peptide Longevity Q&A · 2026-05-02


    Research indicates that SS-31 (Elamipretide) targets mitochondrial dysfunction in atherosclerosis, potentially reducing oxidative stress and inflammatory cytokine secretion. This peptide's mechanism focuses on repairing the mitochondrial electron transport chain, which is crucial for mitigating oxidative damage associated with chronic inflammatory diseases.

 What the research shows

The source paper discusses the role of mitochondrial dysfunction in atherosclerosis, a chronic inflammatory disease characterized by oxidative stress and vascular endothelial dysfunction. It highlights that conventional therapies, such as statins and anti-inflammatory drugs, often fail to address the underlying mitochondrial abnormalities. The paper emphasizes recent advancements in nanotechnology that facilitate targeted mitochondrial delivery systems, including liposomes and nanoparticles. Among these innovations, SS-31 (Elamipretide) is noted for its potential in repairing the mitochondrial electron transport chain and reducing the secretion of inflammatory cytokines. This peptide has progressed to Phase II clinical trials, indicating its relevance in therapeutic strategies aimed at atherosclerosis.

 Why it matters for longevity

The findings suggest that addressing mitochondrial dysfunction could play a significant role in extending healthspan and improving longevity. Mitochondria are central to energy production and cellular metabolism, and their dysfunction is linked to various age-related diseases, including cardiovascular conditions. By targeting mitochondrial health, SS-31 (Elamipretide) may not only alleviate symptoms of atherosclerosis but also contribute to broader longevity strategies that aim to reduce oxidative stress and inflammation, two key factors in the aging process. This aligns with ongoing research into mitochondrial-targeted therapies as a promising avenue for enhancing health in aging populations.

 Key findings at a glance

Atherosclerosis is associated with mitochondrial dysfunction and oxidative stress.

SS-31 (Elamipretide) targets the mitochondrial electron transport chain.

The peptide reduces inflammatory cytokine secretion.

Conventional therapies do not correct mitochondrial abnormalities.

Recent advances in nanotechnology enable effective mitochondrial-targeted delivery systems.

SS-31 has entered Phase II clinical trials for its therapeutic potential.

 How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is designed to specifically target mitochondria, which are crucial for cellular energy metabolism. By repairing the electron transport chain, SS-31 aims to restore normal mitochondrial function, thereby reducing oxidative stress and improving cellular health. This mechanism is particularly relevant in conditions like atherosclerosis, where mitochondrial dysfunction contributes to disease progression. The peptide's ability to mitigate oxidative damage and inflammation positions it as a potential therapeutic agent in age-related diseases.

 Safety, caveats, and what we don't yet know

While SS-31 (Elamipretide) shows promise in targeting mitochondrial dysfunction, further research is needed to fully understand its safety profile and long-term effects. The source paper does not provide specific data on adverse effects or the outcomes of ongoing clinical trials. Additionally, the populations studied to date may not fully represent the broader demographic, necessitating further investigation into its efficacy across diverse age groups and health conditions. This highlights the importance of continued research to establish comprehensive safety and efficacy profiles for SS-31.

 Bottom line

SS-31 (Elamipretide) may effectively reduce oxidative stress associated with atherosclerosis by targeting mitochondrial dysfunction, thus holding potential for enhancing longevity through improved mitochondrial health.

 Related questions

 How does SS-31 (Elamipretide) impact mitochondrial health?

SS-31 (Elamipretide) targets the mitochondrial electron transport chain, aiming to repair dysfunction and improve overall mitochondrial health, which is critical for cellular energy production and reducing oxidative stress.

 What are the potential benefits of mitochondrial-targeted therapies?

Mitochondrial-targeted therapies like SS-31 (Elamipretide) may offer benefits such as reduced oxidative stress, improved energy metabolism, and decreased inflammation, potentially enhancing healthspan and longevity.

 Are there any risks associated with SS-31 (Elamipretide)?

While SS-31 shows promise, ongoing research is needed to evaluate its safety and efficacy in diverse populations. Current studies do not yet provide comprehensive data on potential risks or side effects.

 Source: PubMed · Drug Deliv · published 2026-05-02.

## Sources

- PubMed · Drug Deliv: https://pubmed.ncbi.nlm.nih.gov/41668545/